AR069525A1 - Derivados de isoxazolo- piridazina - Google Patents
Derivados de isoxazolo- piridazinaInfo
- Publication number
- AR069525A1 AR069525A1 ARP080105244A ARP080105244A AR069525A1 AR 069525 A1 AR069525 A1 AR 069525A1 AR P080105244 A ARP080105244 A AR P080105244A AR P080105244 A ARP080105244 A AR P080105244A AR 069525 A1 AR069525 A1 AR 069525A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- hydroxy
- halogen
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a compuestos de la formula (1) en la que X es O o NH; R1 es fenilo, piridinilo, o pirimidinilo, cada uno de ellos está opcionalmente sustituido por 1, 2 o 3 halogenos, R2 es alquilo C1-4, H o haloalquilo C1-4, R3, R4 y R5 con independencia entre si son: H, alquilo C1-7, opcionalmente sustituido por uno o más halogeno, ciano o hidroxi, alcoxi C1-7 opcionalmente sustituido por uno o más halogenos, CN, halogeno, NO2, -C(O)-Ra en el que Ra es hidroxi, alcoxi C1-7; alquilo C1-7, fenoxi o fenilo, NRbRc, en el que Rb y Rc con independencia entre si son: hidrogeno, alquilo C1-7, -C(O)-alquilo C1-7, opcionalmente sustituido por uno o más halogenos, -C(O)(CH2)m-O-alquilo C1-7, en el que m es el numero 0, 1, 2, 3, 4, 5 o 6, -C(O)C(O)O-alquilo C1-7, -C(O)CH2C(O)O-alquilo C1-7, -C(O)Ri, dicho Ri es fenilo o heteroarilo de 5 o 6 eslabones, cada uno de ellos está opcionalmente sustituido por uno o más E, -C(O)-cicloalquilo C3-7, opcionalmente sustituido por uno o más B, -C(O)-Rii, dicho Rii es heterociclilo de 3 a 7 eslabones, opcionalmente sustituido por uno o más A, heterociclilo de 3 a 7 eslabones, opcionalmente sustituido por uno o más A, heteroarilo de 5 o 6 eslabones, opcionalmente sustituido por uno o más E, -C(O)-NRdRe, en el que Rd y Re con independencia entre sí son: H, alquilo C1-7, opcionalmente sustituido por uno o más halogeno, hidroxi, o ciano, -(CH2)t-cicloalquilo C3-7, opcionalmente sustituido por uno o más B y t es el numero 0, 1, 2, 3 o 4, -(CH2)u-O-alquilo C1-7, en el que u es el numero 2, 3, 4, 5 o 6, -(CH2)x-heterociclilo, en el que x es el numero 0, 1, 2, 3 o 4, y dicho heterociclilo está opcionalmente sustituido por uno o más A; Rd y Re junto con el nitrogeno al que están unidos forman un resto heterociclilo opcionalmente sustituido por uno o más A, o R3 junto con el átomo de nitrogeno contiguo de la piridazina forma un anillo aromático fusionado de 5 eslabones con otros dos átomos de nitrogeno del anillo, el anillo fusionado está opcionalmente sustituido por Rf, dicho Rf es alquilo C1-7, -C(O)O-alquilo C1-7, -C(O)-alquilo C1-7, heteroarilo de 5 o 6 eslabones o fenilo, cada uno de ellos está opcionalmente sustituido por uno o más E, A es hidroxi, oxo, alquilo C1-7, alcoxi C1-7, haloalquilo C1-7, hidroxialquilo C1-7, halogeno o CN, B es halogeno, hidroxi, CN, alquilo C1-4 o haloalquilo C1-4, E es halogeno, CN, NO2, hidroxi, alquilo C1-7, alcoxi C1-7, haloalquilo C1-7, hidroxialquilo C1-7, ciano-alquilo C1-7, haloalcoxi C1-7, o cicloalquilo C3-7, o una sal farmacéuticamente aceptable de los mismos que tienen afinidad y selectividad para con l sitio de fijacion del receptor de GABA A alfa5 a su obtencion, medicamentos que contienen los compuestos y al uso de los mismos para preparar medicamentos. Los compuestos activos de la presente son utiles como mejoradores cognitivos o para el tratamiento de trastornos cognitivos, por ejemplo la enfermedad de Alzheimer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07122293 | 2007-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069525A1 true AR069525A1 (es) | 2010-01-27 |
Family
ID=40328910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105244A AR069525A1 (es) | 2007-12-04 | 2008-12-02 | Derivados de isoxazolo- piridazina |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7943619B2 (es) |
| EP (1) | EP2231651B1 (es) |
| JP (1) | JP5301558B2 (es) |
| KR (1) | KR101175855B1 (es) |
| CN (1) | CN101868458B (es) |
| AR (1) | AR069525A1 (es) |
| AU (1) | AU2008333327B2 (es) |
| BR (1) | BRPI0820113A2 (es) |
| CA (1) | CA2707821C (es) |
| CL (1) | CL2008003593A1 (es) |
| IL (1) | IL205753A0 (es) |
| MX (1) | MX2010006182A (es) |
| PE (1) | PE20091446A1 (es) |
| TW (1) | TW200924775A (es) |
| WO (1) | WO2009071477A1 (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2550994T3 (es) | 2007-12-04 | 2015-11-13 | F. Hoffmann-La Roche Ag | Derivados de isoxazol-piridina |
| NZ592603A (en) * | 2008-10-21 | 2013-02-22 | Metabolex Inc | Aryl gpr120 receptor agonists and uses thereof |
| US8227461B2 (en) * | 2009-04-30 | 2012-07-24 | Hoffmann-La Roche Inc. | Isoxazoles |
| JP5466292B2 (ja) * | 2009-05-05 | 2014-04-09 | エフ．ホフマン−ラ ロシュ アーゲー | イソオキサゾール−ピリジン誘導体 |
| SG175780A1 (en) | 2009-05-05 | 2011-12-29 | Hoffmann La Roche | Isoxazole-pyridazine derivatives |
| US8163728B2 (en) * | 2009-05-05 | 2012-04-24 | Hoffmann-La Roche Inc. | Pyrazoles |
| BRPI1011729A2 (pt) * | 2009-05-05 | 2016-03-15 | Hoffmann La Roche | derivados de isoxazol-tiazol como um receptor inverso gaba a agonista para uso no tratamento de distúrbios cognitivos |
| AR081626A1 (es) * | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| CN103189370B (zh) * | 2010-11-09 | 2015-07-08 | 霍夫曼-拉罗奇有限公司 | 作为gaba受体用配体的三唑衍生物 |
| MX346185B (es) * | 2010-11-15 | 2017-03-10 | Agenebio Inc | Derivados de piridazina, composiciones y metodos para tratar deterioro cognitivo. |
| US9586963B2 (en) | 2011-09-27 | 2017-03-07 | Genfit | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists |
| US8604062B2 (en) | 2011-10-20 | 2013-12-10 | Hoffman-La Roche Inc. | Process for the preparation of isoxazolyl-methoxy nicotinic acids |
| ES2748656T3 (es) * | 2011-10-28 | 2020-03-17 | Inhibitaxin Ltd | Derivados de piridazina útiles en terapia |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| US9206160B2 (en) | 2012-06-26 | 2015-12-08 | Saniona Aps | Phenyl triazole derivative and its use for modulating the GABAA receptor complex |
| WO2014001278A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| WO2014001279A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| CN104411703A (zh) | 2012-06-26 | 2015-03-11 | 萨尼奥纳有限责任公司 | 苯基三唑衍生物及其调节gabaa受体复合体的用途 |
| WO2014001280A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| AU2014368961B2 (en) | 2013-12-20 | 2019-10-17 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| AU2016279052A1 (en) | 2015-06-19 | 2018-02-15 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN107344939A (zh) * | 2016-05-06 | 2017-11-14 | 如东赛默罗生物科技有限公司 | 咪唑[2,1-a]酞嗪类衍生物、其制备方法、药物组合物和用途 |
| LT3551627T (lt) | 2016-12-08 | 2022-04-25 | F. Hoffmann-La Roche Ag | Nauji izoksazolilo eterio dariniai kaip gaba a alfa5 teigiami alosteriniai moduliatoriai (pam) |
| US11505555B2 (en) | 2016-12-19 | 2022-11-22 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| EP3807269A1 (en) | 2018-06-13 | 2021-04-21 | F. Hoffmann-La Roche AG | New isoxazolyl ether derivatives as gaba a alpha5 pam |
| EA202190076A1 (ru) | 2018-06-19 | 2021-09-22 | Эйджинбайо, Инк. | Производные бензодиазепина, композиции и способы лечения когнитивных нарушений |
| BR102019014802A2 (pt) * | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| HU231223B1 (hu) | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
| CN112979655A (zh) * | 2019-12-16 | 2021-06-18 | 上海赛默罗生物科技有限公司 | 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途 |
| TW202202495A (zh) | 2020-03-26 | 2022-01-16 | 匈牙利商羅特格登公司 | 作為ｇａｍｍａ－胺基丁酸Ａ受體次單元ａｌｐｈａ ５受體調節劑之㖠啶及吡啶并〔３，４－ｃ〕嗒𠯤衍生物 |
| WO2021191837A1 (en) | 2020-03-26 | 2021-09-30 | Richter Gedeon Nyrt. | 1,3-dihydro-2h-pyrrolo[3,4-c]pyridine derivatives as gabaa α5 receptor modulators |
| EP4334301A1 (en) | 2021-05-05 | 2024-03-13 | University College Cardiff Consultants Limited | Heteroaryl compounds useful in the treatment of cognitive disorders |
| HUP2100338A1 (hu) | 2021-09-29 | 2023-04-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| CN116854680A (zh) * | 2022-03-28 | 2023-10-10 | 上海赛默罗生物科技有限公司 | 异噁唑-杂环类衍生物、药物组合物和用途 |
| WO2024088928A1 (en) * | 2022-10-25 | 2024-05-02 | F. Hoffmann-La Roche Ag | Process for manufacturing alogabat |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3525205A1 (de) | 1984-09-11 | 1986-03-20 | Hoechst Ag, 6230 Frankfurt | Pflanzenschuetzende mittel auf basis von 1,2,4-triazolderivaten sowie neue derivate des 1,2,4-triazols |
| US6297235B1 (en) * | 1997-08-28 | 2001-10-02 | Merck Sharp & Dohme Ltd. | Triazolopyridazine derivatives for treating anxiety and enhancing cognition |
| GB9808663D0 (en) | 1998-04-23 | 1998-06-24 | Merck Sharp & Dohme | Therapeutic agents |
| US6262098B1 (en) * | 1998-08-07 | 2001-07-17 | Chiron Corporation | Estrogen receptor modulators |
| US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| IT1314191B1 (it) | 1999-10-18 | 2002-12-06 | Recordati Chem Pharm | Derivati isossazolcarbossamidici |
| EP1228069B1 (en) | 1999-11-12 | 2003-04-02 | Neurogen Corporation | Bicyclic and tricyclic heteroaromatic compounds |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| GB0108475D0 (en) | 2001-04-04 | 2001-05-23 | Merck Sharp & Dohme | New compounds |
| HUP0401880A2 (hu) | 2001-07-05 | 2005-01-28 | Synaptic Pharmaceutical Corporation | Helyettesített anilin-piperidinek mint MCH-szelektív antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
| ATE381542T1 (de) | 2001-08-13 | 2008-01-15 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
| JP2005518357A (ja) | 2001-11-20 | 2005-06-23 | イーライ・リリー・アンド・カンパニー | ベータ３アドレナリンアゴニスト |
| GB0128160D0 (en) * | 2001-11-23 | 2002-01-16 | Merck Sharp & Dohme | Novel compounds |
| EP1562915A1 (en) | 2002-11-22 | 2005-08-17 | SmithKline Beecham Corporation | Farnesoid x receptor agonists |
| GB0318447D0 (en) | 2003-08-05 | 2003-09-10 | Merck Sharp & Dohme | Therapeutic agents |
| AU2005245411B2 (en) * | 2004-05-14 | 2009-04-23 | Irm Llc | Compounds and compositions as PPAR modulators |
| DE602005007350D1 (de) | 2004-06-01 | 2008-07-17 | Hoffmann La Roche | Pyridin-4-yl-ethynylimidazole und -pyrazole als antagonisten des mglu5-rezeptors |
| JP2008502687A (ja) | 2004-06-14 | 2008-01-31 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| CA2581945C (en) * | 2004-10-01 | 2011-01-18 | Henrietta Dehmlow | Hexafluoroisopropanol substituted ether derivatives |
| WO2006044617A1 (en) | 2004-10-15 | 2006-04-27 | The Scripps Research Institute | Oxadiazole ketone inhibitors of fatty acid amide hydrolase |
| US20070060589A1 (en) | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
| WO2006095882A1 (ja) | 2005-03-07 | 2006-09-14 | Pioneer Corporation | ホログラム装置及び記録方法 |
| WO2006095822A1 (ja) | 2005-03-11 | 2006-09-14 | Ono Pharmaceutical Co., Ltd. | スルホンアミド化合物およびその医薬 |
| EP1899299B1 (en) * | 2005-06-27 | 2010-10-20 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| ATE532668T1 (de) | 2005-07-20 | 2011-11-15 | Prospective Concepts Ag | Pneumatische kissenstrukturen |
| ATE414703T1 (de) | 2005-09-19 | 2008-12-15 | Hoffmann La Roche | Isoxazolderivate als inverse gaba a alpha5 agonisten |
| WO2007052843A1 (ja) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
| JP5081161B2 (ja) | 2005-12-19 | 2012-11-21 | スミスクライン ビーチャム コーポレーション | ファルネソイドｘ受容体アゴニスト |
| JP2007230909A (ja) | 2006-03-01 | 2007-09-13 | Univ Of Tokyo | 置換イソキサゾール誘導体 |
| EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| WO2008130951A1 (en) * | 2007-04-17 | 2008-10-30 | Bristol-Myers Squibb Company | Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors |
-
2008
- 2008-11-25 US US12/277,331 patent/US7943619B2/en active Active
- 2008-11-26 KR KR1020107011907A patent/KR101175855B1/ko not_active IP Right Cessation
- 2008-11-26 CA CA2707821A patent/CA2707821C/en not_active Expired - Fee Related
- 2008-11-26 EP EP08855943.0A patent/EP2231651B1/en active Active
- 2008-11-26 BR BRPI0820113 patent/BRPI0820113A2/pt not_active Application Discontinuation
- 2008-11-26 WO PCT/EP2008/066226 patent/WO2009071477A1/en active Application Filing
- 2008-11-26 MX MX2010006182A patent/MX2010006182A/es active IP Right Grant
- 2008-11-26 AU AU2008333327A patent/AU2008333327B2/en not_active Expired - Fee Related
- 2008-11-26 JP JP2010536410A patent/JP5301558B2/ja not_active Expired - Fee Related
- 2008-11-26 CN CN2008801172173A patent/CN101868458B/zh active Active
- 2008-12-01 TW TW097146621A patent/TW200924775A/zh unknown
- 2008-12-02 PE PE2008002009A patent/PE20091446A1/es not_active Application Discontinuation
- 2008-12-02 CL CL2008003593A patent/CL2008003593A1/es unknown
- 2008-12-02 AR ARP080105244A patent/AR069525A1/es unknown
-
2010
- 2010-05-13 IL IL205753A patent/IL205753A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009071477A1 (en) | 2009-06-11 |
| CN101868458B (zh) | 2012-11-28 |
| MX2010006182A (es) | 2010-07-01 |
| EP2231651B1 (en) | 2018-11-21 |
| CA2707821C (en) | 2016-06-07 |
| US20090143385A1 (en) | 2009-06-04 |
| KR101175855B1 (ko) | 2012-08-24 |
| EP2231651A1 (en) | 2010-09-29 |
| US7943619B2 (en) | 2011-05-17 |
| JP2011505402A (ja) | 2011-02-24 |
| JP5301558B2 (ja) | 2013-09-25 |
| AU2008333327B2 (en) | 2012-12-06 |
| BRPI0820113A2 (pt) | 2015-05-05 |
| PE20091446A1 (es) | 2009-09-24 |
| AU2008333327A1 (en) | 2009-06-11 |
| CN101868458A (zh) | 2010-10-20 |
| KR20100074320A (ko) | 2010-07-01 |
| IL205753A0 (en) | 2010-11-30 |
| CL2008003593A1 (es) | 2010-01-04 |
| TW200924775A (en) | 2009-06-16 |
| CA2707821A1 (en) | 2009-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069525A1 (es) | Derivados de isoxazolo- piridazina | |
| AR069524A1 (es) | Derivados de isoxazolo - pirazina, un procedimiento para la preparacion del compuesto, medicamento en base al compuesto y uso del compuesto para preparar un medicamento | |
| AR069523A1 (es) | Derivados de isoxazolo - piridina | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR053778A1 (es) | Compuestos de quinazolina para el tratamiento de desordenes mediados por la proteina quinasa | |
| AR062074A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa | |
| AR061667A1 (es) | Arilamidas sustituidas con tetrazol | |
| RU2007127849A (ru) | Аналоги тетрагидрохинолина в качестве мускариновых агонистов | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| AR067075A1 (es) | Derivados de isoxasol - imidazol | |
| AR058006A1 (es) | Mimeticos de glucocorticoides, composiciones farmaceiticas y usos de los mismos | |
| AR049652A1 (es) | Sales cuaternarias antagonistas del receptor ccr2 | |
| AR076401A1 (es) | Bisaril alquinilamidas como moduladores alostericos negativos del receptor metabotropico de glutamato 5 (mglur5) | |
| UY29316A1 (es) | Miméticos de glucocorticoides, métodos para prepararlos, composiciones farmacéuticas, y usos de los mismos. | |
| AR078171A1 (es) | Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparacion y uso de las mismas | |
| AR056519A1 (es) | 4-feniltetrahidroisoquinolinas sustituidas, composiciones farmaceuticas que las contienen y usos terapeuticos en trastornos renales, respiratorios y otros | |
| PE20060691A1 (es) | Serinamidas sustituidas por benzoilo | |
| PE20050767A1 (es) | Amino-benzazoles como inhibidores del receptor p2y1 | |
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| PE20070069A1 (es) | Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a | |
| AR047958A1 (es) | Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central. | |
| AR068528A1 (es) | Formas solidas de n-(5-tert-butil-isoxazol-3-il)-n'-(4(7-(2-morfolin-4-il-etoxi) imidazol(2,1-b)(1,3)benzotiazol-2-il)fenil)urea, composiciones con las mismas y usos de los mismos | |
| AR071300A1 (es) | Compuestos; composiciones farmaceuticas en base al compuesto y uso del mismo para la manufactura de un medicamento | |
| AR068734A1 (es) | Esteroides con actividad agonista del receptor de glucocorticoides | |
| AR064831A1 (es) | Derivados de espiropiperidina-glicinamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |